淀粉样蛋白与Tau蛋白PET对诊断及患者管理变化的影响
在记忆门诊队列中,126例注册参与者中84.9%完成研究程序并纳入分析,评估淀粉样蛋白[18F]florbetaben PET与tau PET([18F]PI-2620或[18F]Florzolotau)联合应用与诊断、治疗及管理变化的关系。结果显示联合PET与MCI和痴呆的管理及诊断变化相关,第二代tau PET对诊断和管理变化有较强影响。
要点
- 淀粉样蛋白与tau PET联合应用与MCI和痴呆的管理及诊断变化相关。
- 在全部参与者和痴呆组中,tau PET与管理变化的关联强于淀粉样蛋白PET。
- 病因诊断在CN中变化25.0%,MCI中68.0%,痴呆中23.8%。
核心结论
- 淀粉样蛋白与tau PET联合应用与MCI和痴呆的管理及诊断变化相关,第二代tau PET对记忆门诊的诊断和管理变化有较强影响。
研究设计与样本
- 记忆门诊队列研究,所有参与者接受淀粉样蛋白[18F]florbetaben PET和tau PET([18F]PI-2620或[18F]Florzolotau)。
- 126例注册参与者中84.9%完成研究程序并纳入分析,包括认知正常(CN)40例、轻度认知障碍(MCI)25例、阿尔茨海默病(AD)20例、非AD痴呆22例。
- 痴呆专科医生确定PET前后的诊断(临床综合征和疑似病因)及置信水平,并确定辅助检查和管理方面的患者治疗。
主要发现
- 病因诊断变化:CN组25.0%,MCI组68.0%,痴呆组23.8%。
- PET前后总体管理变化:CN组5.0%,MCI组52.0%,痴呆组38.1%。
- 逻辑回归分析显示,在全部参与者和痴呆组中,tau PET与管理变化的关联强于淀粉样蛋白PET。
关键数值与推荐
- 本研究提供I类证据:淀粉样蛋白与tau PET联合应用与MCI和痴呆的管理及诊断变化相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Previous studies have evaluated the diagnostic effect of amyloid PET in selected research cohorts. However, these studies did not assess the clinical impact of the combination of amyloid and tau PETs. Our objective was to evaluate the association of the combination of 2 PETs with changes in diagnosis, treatment, and management in a memory clinic cohort. METHODS: All participants underwent amyloid [18F]florbetaben PET and tau PET using [18F]PI-2620 or [18F]Florzolotau, which are potentially useful for the diagnosis of non-Alzheimer disease (AD) tauopathies. Dementia specialists determined a pre- and post-PET diagnosis that existed in both a clinical syndrome (cognitive normal [CN], mild cognitive impairment [MCI], and dementia) and suspected etiology, with a confidence level. In addition, the dementia specialists determined patient treatment in terms of ancillary investigations and management. RESULTS: Among 126 registered participants, 84.9% completed the study procedures and were included in the analysis (CN [n = 40], MCI [n = 25], AD [n = 20], and non-AD dementia [n = 22]). The etiologic diagnosis changed in 25.0% in the CN, 68.0% in the MCI, and 23.8% with dementia. Overall changes in management between pre- and post-PET occurred in 5.0% of CN, 52.0% of MCI, and 38.1% of dementia. Logistic regression analysis revealed that tau PET has stronger associations with change management than amyloid PET in all participants and dementia groups. DISCUSSION: The combination of amyloid and tau PETs was associated with changes in management and diagnosis of MCI and dementia, and the second-generation tau PET has a strong impact on the changes in diagnosis and management in memory clinics. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that the combination of amyloid and tau PETs was associated with changes in management and diagnosis of MCI and dementia.
引用
- Shimohama S, Tezuka T, Takahata K, et al. Impact of Amyloid and Tau PET on Changes in Diagnosis and Patient Management. Neurology. 2022. PMID: 36175151. doi:10.1212/WNL.0000000000201389
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。